ReadCrystal

青云瑞晶

ReadCrystal

Biotech/Healthcare

Qingyun Ruijing develops First-in-Class small-molecule targeted innovative drugs based on an internationally leading MicroED drug discovery platform. Its core technical team consists of several returnee PhDs who have published multiple papers in journals such as Nature and Science and possess…

Latest round: Series A (2022)

Source: ChinaBulls — chinabulls.com

Last updated 2022-08-01